An intermediate group with prevalent mutations on both pathways would include endometrial carcinoma (PIK3CA 57%, KRAS 21%), colorectal adenocarcinoma (PIK3CA 31%, KRAS 51%), or gastric adenocarcinoma (PIK3CA 24%, KRAS 16%). This evidence concerns the gene PIK3CA and endometrial carcinoma.